Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design.

Recurrent disease after BCG presents a therapeutic challenge. To aid trial development, the US Food & Drug Administration defined ‘adequate BCG’ therapy and adopted the ‘BCG unresponsive’ disease state.